Solid Solution Lipid Composition for Targeted Sustained Pain Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for severe pain are limited, often requiring frequent dosing and causing undesirable systemic side effects, and do not provide complete pain relief, highlighting the need for a therapeutic option that offers sustained relief while minimizing side effects.
Innovation Solution
A solid solution pharmaceutical composition comprising propionic acid derivative NSAIDs, room temperature solid lipids, and liquid lipids, formulated to create a lipid-adjuvant delivery system that effectively targets therapeutic compounds to inflamed tissues using chylomicrons and dendritic cells, allowing for sustained pain relief.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional pain therapies are used, then pain relief is achieved, but frequent dosing is required and systemic side effects occur
Solution Approach 1:
The patent applies local quality by formulating the NSAID in a solid solution with specific lipid components (triglycerides, monoglycerides, diglycerides) that enable targeted delivery to inflamed tissues through chylomicrons. This localized delivery mechanism concentrates the therapeutic compound at the site of pain while minimizing distribution to other body systems, thereby reducing systemic side effects while maintaining pain relief effectiveness.
Solution Approach 2:
The patent uses lipid molecules as intermediaries to carry the NSAID from the gastrointestinal tract to inflamed tissues. The solid solution formulation with specific lipid ratios (triglycerides 50-90%, monoglycerides 5-30%, diglycerides 5-30%) creates a delivery vehicle that mediates between the drug and target tissue, enabling sustained release and targeted accumulation in inflamed areas while avoiding widespread systemic exposure.
2Reliability
If conventional pain therapies are used, then pain relief is achieved, but multiple medications are required and drug-drug interactions occur
Solution Approach 1:
The patent merges the NSAID with specific lipid components in a single solid solution formulation. This combination creates a unified therapeutic product that eliminates the need for multiple separate medications, simplifying the patient regimen while maintaining effective pain relief through the synergistic action of the lipid-adjuvant delivery system.
3Reliability
If conventional pain therapies are used, then pain relief is achieved, but complete pain relief is not provided
Solution Approach 1:
The patent achieves continuous pain relief through the solid solution formulation that provides sustained release of the NSAID. The lipid-based delivery system ensures continuous accumulation of the drug in inflamed tissues over time, maintaining therapeutic levels and providing prolonged pain relief without the need for frequent dosing interruptions.
4Ease of operation
If solid solution formulation is used, then targeted delivery to inflamed tissues is achieved, but formulation complexity increases
Solution Approach 1:
The patent achieves targeted delivery by carefully controlling the physical and chemical parameters of the solid solution formulation. Specific ratios of lipid components (triglycerides 50-90%, monoglycerides 5-30%, diglycerides 5-30%) and the melting point range (30-45°C) are optimized to enable proper solubility, stability, and biological activity. These parameter optimizations allow the complex formulation to function effectively while maintaining manufacturability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition provides targeted and sustained pain relief by effectively inhibiting pain responses in inflamed tissues, reducing pain by up to 100% in various types of pain, while minimizing systemic side effects.
Implementation Method 1
The composition provides targeted and sustained pain relief by effectively inhibiting pain responses in inflamed tissues
Implementation Method 2
formulated to create a lipid-adjuvant delivery system that effectively targets therapeutic compounds to inflamed tissues using chylomicrons and dendritic cells
Implementation Method 3
The composition provides targeted and sustained pain relief by effectively inhibiting pain responses in inflamed tissues
Data Source
Figure 1A~1B
Figure 1C~1D
Figure 1E~1F
AI summary
The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a severe pain in an individual using such pharmaceutical compositions.